explore -WSS

explore

author：hotspot 2025-10-01 07:40:38 - browse：89898

Vivistim and Lead — A small Texas company is testing whether pairing vagus nerve stimulation with rehabilitation exercise can restore movement in people who have had a stroke. STAT/MicroTransponder, Inc.

Despite being forced by Hurricane Irma to close its outpatient facilities for several days, the Mayo Clinic in Jacksonville, Fla., is expected to forge ahead this month with a pivotal clinical trial testing whether an electrical implant can rewire the brains of stroke patients so they can use their arms and hands again.

If the patients who receive implants regain significantly more function than those who get only standard rehabilitation, it will show that stroke-damaged brain circuits can be bypassed like shorts in a circuit board, with healthy neurons coaxed into performing the job of those fried by stroke.

Although the results might not be make-or-break for the little 11-year-old Texas company sponsoring the trial (called MicroTransponder, the company’s also testing whether an electrical implant can alleviate tinnitus), there will be more evidence of whether “electroceuticals” — electrical stimuli tailored to treat diseases — work beyond their current use in controlling pain and a few other conditions or will fall short of the buzz surrounding them.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： The Affordable Care Act has saved billions in health care costs

focus

WSS

Why you shouldn’t ask, “What country has the best health care?”

Wegovy, Zepbound and weight loss drugs that preserve muscle

Biogen walks away from Aduhelm, years after polarizing approval

Why medical students are struggling with mental health

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Gain of function research would be limited under House proposal

knowledge

explore

explore

Virginia high school admissions case could be legal follow

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Trump demands the U.S. pay no more for drugs than other countries … again

Boston competes with Raleigh

Psychedelics group wrestles with new pharma identity

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Malaria cases in Florida and Texas: Here’s what you need to know

Surge of respiratory disease in China has likely explanation

Apple is now the first public company to be valued at $3 trillion

PBM reforms clear House panel

entertainment

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Merck, Johnson & Johnson CEOs will testify on high drug prices

Wegovy leads to weight loss. Can it treat depression, too?

New clues to why women have higher risk of autoimmune disorders

Morphosys mixed study results for blood cancer drug

Biogen walks away from Aduhelm, years after polarizing approval

focus

focus

explore

knowledge